Ruth Casey, Cambridge – In vivo and ex vivo metabolomics in succinate dehydrogenase deficient tumorigenesis. View details
Vasilieos Chortis, Birmingham – Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma. View details
Donato Iacovazzo, London – A missense mutation in the islet-enriched transcription factor MAFA leads to familial insulinomatosis and diabetes. View details
Kate Lines, Oxford – Treatment with the epigenetic modifying compound JQ1+ can significantly reduce the proliferation of pancreatic neuroendocrine tumours in a mouse model of multiple endocrine neoplasia type 1 (MEN1). View details.
Umasuthan Srirangalingam, London – SDHB surveillance regime – a single UK institution experience.
Judit Dénes, London – Pituitary adenoma and phaeochromocytoma/paraganglioma – a novel syndrome with a heterogeneous genetic background
Candy Sze, London – Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?
Giampaolo Trivellin, London – miR-107 inhibits the expression of aryl hydrocarbon receptor interacting protein (AIP) and is potentially involved in pituitary tumorigenesis
Zehra Ozfirat, London – Geographical cluster of familial isolated pituitary adenoma kindreds with an identical AIP mutation
Angela Taylor, Birmingham – Development of urinary steroid profiling as a high-throughput screening tool for the detection of malignancy in patients with adrenal tumours